[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635424":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":29,"responsibleParty":100,"collaborators":102,"id":110,"slug":111,"hasResults":112,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":11,"eligibilityCriteria":115,"healthyVolunteers":112,"sex":116,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":11,"studyType":122,"phases":123,"briefSummary":125,"conditions":126,"keywords":130,"overallStatus":134,"whyStopped":11,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":144},{"fullName":5,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Goserelin group","EXPERIMENTAL",null,[13],"Drug: Goserelin Depot",{"label":15,"type":16,"description":11,"interventionNames":11},"Control group","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Goserelin Depot","Subcutaneous injection of 3.6 mg of goserelin acetate once, administered 1 to 3 days prior to allogeneic haematopoietic stem cell transplantation conditioning.",[9],[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"wei shi","CONTACT","86-13207131315","496020121@qq.com",[30,48,63,70,85],{"facility":31,"status":11,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan","450000","China","CN",{"type":38,"coordinates":39},"Point",[40,41],113.64861,34.75778,{"lat":41,"lon":40},[44],{"name":45,"role":26,"phone":46,"phoneExt":11,"email":47},"jie wei Cao","86-15093360671","15093360671@163.com",{"facility":49,"status":11,"city":50,"state":51,"zip":52,"country":35,"countryCode":36,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan","Hubei","430000",{"type":38,"coordinates":54},[55,56],114.26667,30.58333,{"lat":56,"lon":55},[59],{"name":60,"role":26,"phone":61,"phoneExt":11,"email":62},"yang Cao","86-13986142606","13986142606@163.com",{"facility":5,"status":11,"city":50,"state":51,"zip":52,"country":35,"countryCode":36,"cosmosGeoPoint":64,"geoPoint":66,"contacts":67},{"type":38,"coordinates":65},[55,56],{"lat":56,"lon":55},[68],{"name":69,"role":26,"phone":27,"phoneExt":11,"email":28},"wei Shi",{"facility":71,"status":11,"city":72,"state":73,"zip":74,"country":35,"countryCode":36,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"The First People's Hospital of Yunnan Province","Kunming","Yunnan","650000",{"type":38,"coordinates":76},[77,78],102.71833,25.03889,{"lat":78,"lon":77},[81],{"name":82,"role":26,"phone":83,"phoneExt":11,"email":84},"jie ya Wang","86-13211630338","13211630338@163.com",{"facility":86,"status":11,"city":87,"state":88,"zip":89,"country":35,"countryCode":36,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"The First Affiliated Hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang","310000",{"type":38,"coordinates":91},[92,93],120.16142,30.29365,{"lat":93,"lon":92},[96],{"name":97,"role":26,"phone":98,"phoneExt":11,"email":99},"min yan Zhao","86-15858199217","15858199217@163.com",{"type":101,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[103,105,107,108],{"name":104,"class":6},"Wuhan TongJi Hospital",{"name":106,"class":6},"Zhejiang University",{"name":31,"class":6},{"name":109,"class":6},"The First People's Hospital of Yunnan","100635424","clinical-study-on-the-preservation-of-ovarian-function-in-patients-with-aplastic-anemia-following-allogeneic-hematopoietic-stem-cell-transplantation-using-goserelin-100635424",false,"NCT07552506","Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin","Inclusion Criteria:\n\n(1) Patients clinically diagnosed with SAA and scheduled for allogeneic haematopoietic stem cell transplantation (allo-HSCT); (2) Female patients aged 14 to 50 years, within reproductive age, with regular menstrual cycles prior to transplantation; (3) Patients or their legal representatives voluntarily participate and sign informed consent forms, demonstrating comprehension and willingness to comply with all study procedures and requirements; (4) Patients with an estimated survival period exceeding one year to ensure sufficient time for monitoring menstrual recovery.\n\nExclusion Criteria:\n\n(1) Patients with severe dysfunction of vital organs such as the heart, liver, or kidneys, which may compromise study outcomes or increase patient risk; (2) Patients with a history of allergy to goserelin or related medications; (3) Patients who have previously undergone menopause due to physiological or pathological factors; (4) Patients with a history of gynaecological conditions (e.g., polycystic ovary syndrome, endometriosis) that may interfere with the assessment of menstrual recovery; (5) Patients currently participating in other clinical studies that may influence menstrual recovery; (6) Patients who refuse to participate in this clinical study.","FEMALE","14 Years","50 Years",{"count":120,"type":121},132,"ESTIMATED","INTERVENTIONAL",[124],"NA","This study is a prospective, randomized, controlled, multicenter clinical trial. It plans to enroll 132 female SAA patients aged 14-50 years from multiple medical centers nationwide who are scheduled to undergo allo-HSCT. Patients will be divided into two groups based on whether they receive busulfan conditioning: the busulfan-conditioned group (Bu group) and the non-busulfan-conditioned group (non-Bu group). Within each group, patients will be randomly assigned 1:1 to either the experimental group (Goserelin prophylaxis group) or the control group using a random number table. The experimental group will receive a single 3.6 mg subcutaneous injection of Goserelin 1-3 days prior to conditioning, in addition to the standard transplantation regimen. The control group will not receive Goserelin prophylaxis. The primary endpoint was menstrual recovery rate at 6 months post-transplant (defined as ≥3 naturally occurring menstrual cycles without intervention by menstrual-regulating drugs). Secondary endpoints included: incidence of premature ovarian insufficiency (POI); ovarian reserve function markers: anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels; Additional reproductive parameters: ovarian and uterine volume, endometrial thickness; time to neutrophil\u002Fplatelet engraftment; incidence of acute\u002Fchronic graft-versus-host disease (aGVHD\u002FcGVHD), EBV\u002FCMV infection rates; transplant-related mortality; and adverse event (AE) occurrence. This study aims to evaluate the efficacy and safety of goserelin in preserving ovarian function following allo-HSCT.",[127,128,129],"Aplastic Anaemia (AA)","Allogeneic Haematopoietic Stem Cell Transplantation","Ovarian Insufficiency",[131,132,133],"Aplastic anaemia","Allogeneic haematopoietic stem cell transplantation","Ovarian insufficiency","NOT_YET_RECRUITING","2026-04-20",{"date":137,"type":138},"2026-04-27","ACTUAL",{"date":140,"type":121},"2026-05-01",{"date":142,"type":121},"2027-10-01",{"name":5,"class":6},5]